Figure 11 Sensing responses of CNT and Au-CNT samples towards the detection of hydrogen (H 2 ). Behaviour of pure CNTs (a) and hybrid Au-CNT samples prepared by dip-coating (b) and drop-casting (c). Maximum sensitivity value for each peak as a function of H2 concentration (d). Solid line in d graph represents the linear fit to these

RG7204 nmr data points. In both cases, CNT and Au-CNT hybrids, increased resistance under acetylene or hydrogen exposure has been detected. This behavior is typical of p-type semiconductors exposed to electron donor gases, since these species induce a reduction of the density of holes [59]. Particularly for Au-CNT hybrid nanostructures, the sensing mechanism could be explained by two process: (1) the adsorption of gases in the side walls of CNTs, with the simultaneous charge transfer between

the target molecule and the CNT network; and (2) the gold nanoclusters could be producing a catalytic spillover effect, in which the electron donor gases are chemisorbed and their electrons transferred from the gold particles to the CNT, decreasing the conductivity of the p-type material. It is worth mentioning at this point that the presence of the AuNPs can modify the catalytic activity of the hybrids not only due to the presence of the particles themselves but also because of the structural changes they induce in the walls of the CNTs, thus modifying the intrinsic chemical affinity of the tubes. The difference in sensitivity of the gold-modified CNTs in this report, SCH772984 solubility dmso Progesterone compared to previous reports [59, 60], could be due to the lower density of NPs used in the

course of this study. This report indicates that hybrid materials formed by AuNPs, encapsulated by the CNTs, are useful as sensing elements; nevertheless, further characterizations are indeed required in order to incorporate them in practical devices. Conclusions Through the procedures described in this report, we have indeed formed a nanoscale reactor with physical dimensions that can be designed by adjusting the synthesis procedure. These reactors are fairly uniform in diameter and while protected by AAOs, added particles, precursors, or molecules only can access the inside of the tubes. As a way to prove the effectiveness of this strategy, we have selectively located Au ions inside the tubes’ cavities. Depending on the preparation conditions, the AuNPs can be made to evolve from small NPs, with diameter only dependent on the precursor concentration, to larger conglomerates with sizes that are fixed by the CNT’s confinement. The alumina can be easily dissolved releasing the new CNT-particle hybrids. From the study of the conductance as a function of temperature, we found that the dominant transport mechanism in the CNTs_(AAO/650°C) and the Au-CNTs samples is the intra-tube 1D hopping. This is consistent with the fact the CNTs’ walls contain a considerable fraction of amorphous carbon.

Spine J 11:737–44PubMedCrossRef 64. Drummond M, Barbieri M, Cook J et al (2009) Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 12:409–18PubMedCrossRef”
“Introduction Nitrogen-containing bisphosphonates (N-BP) are prescribed for the treatment of bone diseases such as osteoporosis, multiple myeloma, cancer metastases, and Paget’s disease. However, bisphosphonate-related osteonecrosis of the jaws (BRONJ) has been reported as a rare complication. BRONJ occurs at a much higher rate in patients selleckchem receiving intravenous N-BPs for cancer treatment

versus oral N-BPs. The incidence of BRONJ in patients treated for osteoporosis is low at 0.1 %, but the incidence of BRONJ in cancer patients treated with high doses of intravenous N-BP is higher at 3 to 10 % [1]. Currently, conservative treatment is recommended for BRONJ, in accordance with the American Association of Oral and Maxillofacial Surgeons (AAOMS) Position Paper [2]. Recently, however, it has been reported that daily parathyroid hormone treatment is effective for BRONJ. Weekly teriparatide (TPTD; human parathyroid hormone peptide 1–34) injections have been used to treat osteoporosis in Japan [3], but there are no reports describing the effectiveness

of weekly TPTD injections for the treatment of BRONJ. Management of BRONJ is challenging and controversial, and there is currently no established drug treatment selleck for this condition. We report two patients with stage 3 BRONJ. One patient was successfully treated with weekly PTD injections, and the other with daily TPTD injections. Changes in the levels of serum N-telopeptide of type I collagen (s-NTX) and serum N-terminal propeptide of type I collagen (P1NP) were studied. Case reports Case 1 An Aurora Kinase 87-year-old Japanese woman with a 4-year history of alendronate therapy

(35 mg/week orally) was referred for the treatment of multiple fistulas with purulent discharge over the left maxillary ridge. She was diagnosed with stage 3 BRONJ according to the AAOMS guidelines (2009). She initially received conservative treatment, including instruction on oral hygiene, administration of antibiotics, antimicrobial mouth gargles, and local irrigation. N-BP therapy was discontinued at the time of her first visit. Three months later, she underwent sequestrectomy and extraction of the maxillary left first and second molars because of high tooth mobility (Fig. 1a, d, g). We continued conservative therapy and debridement for 1 year. However, her disease was persistent and progressive (Fig. 1b, e, h). She was then treated with TPTD by subcutaneous injection (56.5 μg weekly). After 3 months of TPTD treatment, there was complete coverage of the necrotic tissue and exposed bone with normal mucosa. Computed tomography showed that her maxillary sinusitis attributed to stage 3 BRONJ had resolved (Fig. 1c, f, i).

It is connected to a PC and a UNICORN TM software, that allows to control, manage and monitor the process and its parameters. The supernatant

was ultrafiltered on 5KDa membranes with a filtering area of 0.1 m2 and diafiltered with 5 volumes of distilled water. After CT99021 cost addition of 0.08 M NaCl the recovered retentate was precipitated with 6 volumes of acetone and ethanol (1:1 v/v). The precipitate was dried, resuspended in sterile water and treated with active charcoal to decolorization and purification from accidental endotoxin contamination. Finally the concentrated EPS solution was microfiltered on 0.22 μm membranes and lyophilized. The powder obtained was used for further characterization. General analytical and spectroscopic methods Determination of sugars residues and of their absolute configuration, GLC and GLC-MS were all carried out as described. 1D 2D NMR experiments were carried out as described [44, 45]. Culturing of Vk2/E6E7cells Vk2/E6E7, immortalized human vaginal epithelial cell line (American Type Culture Collection), were grown in 75-cm2 flasks (Falcon, Becton Dickinson Biosciences, Milan, Italy) at 37°C (5% CO2) in Keratinocyte-Serum Free medium (GIBCO-BRL San Giuliano

Milanese, Milan, Italy) with 0.1 ng∙ml−1 human Thymidylate synthase recombinant EGF, 0.05 mg∙ml−1 bovine pituitary extract, and additional calcium to a final concentration BYL719 cost of 0.4 mM. The medium was changed every 2 days. Confluent monolayers (2.5 × 105 cells) were grown in six-well tissue culture

plates (Falcon, Becton Dickinson Biosciences, Milan, Italy) in Dulbecco’s modified Eagle’s medium and Ham’s F12 medium (D-MEM) (GIBCO-BRL San Giuliano Milanese, Milan, Italy), antibiotic-free and FCS-free, for 24 h, before starting experiments. One million Vk2/E6E7 cells/well were used for the adhesion assay. Adhesion of L. crispatus L1 to Vk2/E6E7 cells and competition with C. albicans for adherence Cell suspensions of L. crispatus L1 were grown in MRS broth at 37°C in anaerobic conditions. C. albicans was identified on the basis of growth characteristics, colony morphology, cellular appearance, and carbohydrate assimilation patterns using commercially available ATB ID 32 C test kit (bioMérieux, Marcy/Etoile, France) at the Operative Unit of Microbiology, Second University of Naples, Italy. Yeast cells were prepared by inoculating four colonies isolated from Saburaud agar (Oxoid, Milan, Italy) plates in 6 ml Brain Heart infusion broth (BHI broth) (Oxoid, Milan, Italy), and incubating the suspension at 30°C for 18 h under constant shaking.

S. aureus were then serially diluted and spread-plated on nutrient agar. Bacterial viability was assessed by counting the number of colonies formed on the agar plate. The colony

count was normalized by considering the untreated colony (negative) as 100% of bacteria viability. The viability of E. coli and P. aeruginosa after 24 h was determined by turbidity measurements (OD600nm), taking into account background caused by the NPs themselves. Effect of NO/THCPSi NPs on established biofilms The reduction in total viable cells recovered from established S. epidermidis biofilms treated with NO/THCPSi NPs was compared to the control biofilms of the same species Trametinib molecular weight not treated with the NPs. Glass microscope slides were cut into pieces with surface areas of 24 mm2. The glass pieces were cleaned with 70% ethanol and dried. S. epidermidis was cultured at 37°C in TSB overnight and diluted to

106 CFU/mL. The 106 CFU/mL microbial suspension was then added to each tube containing the glass slide pieces. The vials containing bacteria, broth, and glass slide pieces were placed in a 37°C incubator for biofilm formation. After 24 h, the glass slide pieces were removed from the nutrient broth, rinsed twice in sterile PBS, and individually transferred into new Eppendorf tubes containing a fresh suspension 1 mL of 0.1 mg/mL NO/THCPSi NPs and THCPSi NPs (control) in PBS and returned to the 37°C incubator. After 24 h, the tubes click here containing glass slide pieces were sonicated in a 125-W ultrasonic cleaner for 5 min to remove the biofilm-forming cells from the slide. The resulting bacterial suspension was subjected to serial tenfold dilutions, and 100 μL of appropriate dilutions

was plated onto agar plates, which were then incubated at 37°C overnight. The total number of colonies that grew on each plate was counted, and the number of viable biofilm bacteria removed from each slide was determined. Mammalian cell viability assay The cytotoxicity of the NO/THCPSi NPs was evaluated using NIH/3T3 fibroblast cells. The cells were maintained in DMEM supplemented with 10% FBS and 2 mM l-glutamine, Thiamine-diphosphate kinase 100 U/mL penicillin, 100 μg/mL streptomycin, and incubated at 37°C with 5% CO2. All mentioned procedures for the preparation of NO/THCPSi NPs and glucose/THCPSi NPs were done under sterile conditions within a biological safety cabinet (Bio-cabinet, Aura 2000, Microprocessor Automatic Control, Firenze, Italy). The NIH/3T3 cells were trypsinized and then seeded into polystyrene 96-well plates (Nalge Nunc International, Penfield, NY, USA) at a density of 3 × 104 cells/mL and then after 24 h, the cultured cells were incubated with NO/THCPSi NPs, glucose/THCPSi NPs, and THCPSi NPs at four different concentrations from 0.05 to 0.2 mg/mL for 48 h. After the incubation period, the culture medium was separated from the cultured cells and subjected to a LDH assay that was carried out following the manufacturer’s instructions.

Quantification was done by a pre-programmed logarithm directed specifically in the identification of caspase 3 and TUNEL stained slides. Statistical analysis Statistical analysis was done by 2-sample equal variance t-Test. Significance was set at p ≤ 0.01. Results In-vivo observations Significant changes in body weights and clinical signs were not observed for the 7-day duration of the study. There were no unscheduled deaths in the study or significant changes found during gross examination. Angiogenesis inhibitor Differences in liver weight between controls and treated animals were

not observed. Histology No significant morphologic changes were observed in the livers of compound-treated or control rats (data not shown). Differences between liver lobes were not detected. Caspase 3 and TUNEL Few caspase 3 and TUNEL positive cells were seen in the livers of both treated and control rats. No significant statistical differences between these groups were detected using Selleckchem Buparlisib morphometry. Clinical pathology ALT, ALP, and AST activity was measured in the serum of compound-treated and control rats and results are presented in Table 1. On day 3 of treatment, AG28262 induced a statistically significant increase in serum ALT activity

(63%; p ≤ 0.01) compared to controls. On day 8, ALT activity progressively increased by approximately 2-fold compared to the control group, a statistically significant difference (p ≤ 0.01). There was a progressive increase in serum ALP activity from day 3 to day 8 in treated animals, and the increase in treated rats at day 8 was statistically significant compared to Baricitinib controls. Serum AST activity in treated rats was increased by 63% on day 8 compared to the control rats but the increase was not statistically significant due to individual variability. Table 1 Effect of AG28262, a VEGR-2 inhibitor, on serum ALT, ALP and AST enzymatic activity in treated and control rats Group Day sampled ALT (U/L) ALP (U/L) AST

(U/L) Control 3 53 ± 2 175 ± 15 99 ± 3 400 mg/kg 3 82 ± 7 * 197 ± 16 111 ± 1 Control 8 55 ± 4 153 ± 12 89 ± 2 400 mg/kg 8 118 ± 19* 209 ± 15* 150 ± 40 Values expressed as mean U/L ± SEM. *Statistically significant (p ≤ 0.01). AG28262-induced effect on ALT gene expression In the right medial lobe, AG28262 treatment resulted in a 49% increase ALT gene expression compared to the control animals on day 8 (Figure 1). Relative expression of ALT in the left lateral liver lobe at day 8 of termination was not significantly different from the control group (Figure 2). The caudate lobe had a statistically significant (p ≤ 0.01) increase in ALT gene expression of 63% in comparison to the control group (Figure 3). Figure 1 Effect of AG28262, a VEGR-2 inhibitor, on ALT gene expression and enzymatic activity in the right medial liver lobe. Relative gene expression values are reported as mRNA ALT/mRNA beta-actin. * Statistically significant (p < 0.01).

, distal ascospore cell 5–10 × 4.3–7.0 μm H. sulphurea (3E) 19′ On basidiomes JAK inhibitor of Eichleriella deglubens; distal ascospore cell 3.7–6.5 × 3.0–5.0 μm H. austriaca (3E) 20 On effused basidiomes of Phellinus spp. H. phellinicola (3E) 20′ On other polypores 21 21 On Fomitopsis pinicola and Piptoporus betulinus; stromata subpulvinate or effuse, (greenish-, brownish-) yellow pigment concentrated around the ostioles; surface velutinous to farinose due to numerous verrucose hairs; ascospore cells monomorphic;

apical ostiolar cells lanceolate H. pulvinata (3E) 21′ On Fomitopsis pinicola; stromata effuse; brownish pigment homogeneously distributed; surface if farinose only due to spore powder; ascospore cells dimorphic; ostiolar cells not lanceolate H. protopulvinata (3E) 22 On forest litter and soil, spreading from stumps, less commonly on attached bark; stromata whitish, yellow or cream to pale ochre; cortical tissue pseudoparenchymatous; distal ascospore cell 3.7–5.8 × 3.5–4.8 μm H. citrina (3E) 22′ On wood and bark, overgrowing various fungi; stromata selleck compound light yellow to light brown, cortical tissue prosenchymatous, distal ascospore cell 3.0–3.7 × 3.0–3.5 μm; in Europe only known from southern France H. decipiens (3E) 23 Stromata effuse to subpulvinate,

to several cm long; surface glabrous; yellow or orange; conidia green, at least in mass 24 23′ Stromata of different shapes, smaller; when effuse then surface hairy; conidia green or hyaline 27 24 Stromata effuse, up to 5 cm long, yellow; cortex of minute thick-walled labyrinthine cells; distal ascospore cell 2.3–4.3 × 2.3–3.2 μm; conidiation effuse, verticillium-like; conidia green on SNA,

at least in mass H. luteffusa (2P) 24′ Cortical cells minute but not labyrinthine; distal ascospore cell larger, 3–6 × 3–5 μm 25 25 Stromata pale yellow when fresh, subeffuse, discoid to pulvinate; conidiation on PDA in well-defined green zones, colony radius 32–34 mm on CMD Alanine-glyoxylate transaminase at 25°C after 3 days H. rodmanii (4B) 25′ Stromata with brighter colours, effuse to subpulvinate 26 26 Stromata bright yellow to bright orange, usually associated with brown rhizomorphs; growth slow, colony radius 4–6 mm on CMD at 25°C after 3 days; mycelium on CMD forming several concentric zones of equal width H. auranteffusa (4B) 26′ Stromata bright yellow, up to 2 cm diam, reminiscent of H. sulphurea; colony radius 22–28 mm on CMD at 25°C after 3 days; mycelium on CMD forming several concentric zones of unequal width; only known from Kärnten, Austria H. margaretensis (4B) 27 Ascospore cells monomorphic 28 27′ Ascospore cells dimorphic, proximal cell typically narrower than distal cell 30 28 Stromata green to grey, discoid, often undulate; ostioles green in lactic acid; on exposed wood; growing at and above 35°C; anamorph green-conidial H.

Clin Selleck CCI-779 Cancer Res 2011, 17:7808–7815.PubMedCrossRef 33. Nakamura T, Sueoka-Aragane N, Iwanaga K, Sato A, Komiya K, Abe T, Ureshino N, Hayashi S, Hosomi T, Hirai M, Sueoka E, Kimura S: A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA. J Thorac Oncol 2011, 6:1639–1648.PubMedCrossRef 34. Kim HJ, Lee KY, Kim YC, Kim KS, Lee SY, Jang TW, Lee MK, Shin KC, Lee GH, Lee JC, Lee JE, Kim SY: Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for

epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer 2011, 75:321–325.PubMedCrossRef 35. Han HS, Lim SN, An JY, Lee KM, Choe KH, Lee KH, Kim ST, Son SM, Choi SY, Lee HC,

Lee OJ: Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential MI-503 order sensitivity. J Thorac Oncol 2012, 7:355–364.PubMedCrossRef Competing interests The authors had no competing interest to declare. Authors’ contributions YCK, SHJ, KYL and JCL contributed to study conception and design. SYL, DSH, MKL, HKL, CMC, SHY, YCK and SYK were involved in acquisition and analysis of data, HRK and JCL wrote the manuscript. KYL confirmed the final draft. All authors read and approved the final manuscript.”
“Introduction Osteoporosis is a complex disease,

and many factors may contribute to the skeletal fragility that underlies osteoporotic fractures [1]. Two processes are thought to be particularly important in post-menopausal osteoporosis. First, during adult life, in both men and women, resorption of bone tends to exceed bone formation at each of the basic multicellular units that are responsible for bone remodelling. Secondly, relative oestrogen deficiency in women after the menopause increases the rate of bone remodelling, accelerating the net Progesterone loss of bone [2, 3]. During long-term treatment, anti-resorptive anti-osteoporotic agents act primarily by decreasing the rate of bone remodelling [4]. For example, during treatment with the bisphosphonate alendronate, some biochemical markers of bone resorption show a rapid decrease of 50% to 65% within 1 month of treatment. However, this is accompanied by a delayed decrease in markers of bone formation of approximately 50%, which reaches a nadir between 6 and 12 months [5]. It might be predicted that baseline bone turnover rates could influence the effects of treatment with anti-resorptive and other anti-osteoporotic agents. For example, anti-resorptive agents might be expected to be of greatest benefit to women with high levels of bone turnover, while bone formation agents might be most effective in women with low rates of bone formation.

Figure 7 Induction of capsule production by IPTG in S. aureus Newman-132. CP5 was labelled by immunofluorescence (CY3, green), the cells were stained using DAPI (blue). Cells were grown for 6 h in MH medium at 37°C. a) S. aureus Newman (control) b) S. aureus Newman in the presence of 0.5 mM IPTG; c) S. aureus Newman-132 harbouring pMUTIN4 in the capsule

promoter in the absence of IPTG and d) S. aureus Newman-132 harbouring pMUTIN4 in the capsule promoter after induction with IPTG. As capsule production in SA1450/94 might be impaired by the insertion of IS256 described above, it was attempted to reconstitute CP5 production. In S. aureus Newman insertion of Tn916 into cap5A1 could be repaired by complementation of cap5A1 in Dabrafenib concentration trans [34]. Therefore, a similar construct (pCapAre) was introduced into SA1450/94, which increased capsule production compared to the parent strain (Figure 8). However, full capsule production was not achieved and the vancomycin MIC of the find more clone remained unchanged compared to SA1450/94. Figure 8 Capsule production of different S. aureus SA1450/94 clones. CP5 was labelled by immunofluorescence (CY3, green), the cells were stained using DAPI (blue). Cells were grown for 6 hours in BHI medium at 37°C. a) S. aureus SA1450/94 harbouring pCapAre, which has reconstituted capsule production; b) SA1450/94 (control)

and c) SA1450/94 harbouring pCU1 (vector control). Furthermore, a capsule knockout mutant of strain Reynolds had previously

been tested against vancomycin, and no differences in susceptibility to vancomycin were recorded [62]. Population analyses in our laboratory confirmed this result (data not shown). Effect of capsule material on the susceptibility of staphylococci to vancomycin In order to test whether capsule material Smoothened is able to interact with or bind to vancomycin, crude capsular material was prepared from S. aureus 137/93G and S. aureus NCTC 8325 (negative control; as shown in Figure 6 for S. aureus HG001, the strains of this lineage do not produce a capsule unless cap5E is repaired). Cell wall teichoic acid that might contaminate the extracts was removed by periodate oxidation. The material was added to MIC determinations using S. aureus NCTC8325 and S. aureus SG511 as indicator strains in MH medium. There was no significant difference in the MIC values between the extract containing capsular material and the controls for S. aureus SG511, however a small effect (0.7 mg/L increase in the MIC) was visible with S. aureus NCTC8325 and the extract of S. aureus SA137/93G. The test was repeated 8 times with two different preparations of the capsular material; an additional DNase and RNase digest did not influence the result. While we cannot explain this difference, the fact that no increase in the MIC was visible with the more susceptible indicator strain strongly indicated that the type 5 capsular material did not neutralise the effect of vancomycin in this assay.

pseudomallei 1026b. Despite these differences, our data constitute independent proof of the role of BpaC as an adhesin. These results are substantiated by showing that expression of BpaC on the surface of recombinant E. coli bacteria increases adherence to NHBE, A549

and HEp-2 cells (Figure  2). Given the phenotype of mutants in assays with NHBE cultures and that adherence is a key step in pathogenesis by most infectious agents, we expected the bpaC mutation to reduce the virulence of B. mallei and/or B. pseudomallei in a mouse model of aerosol infection. However, the results of our animal experiments indicate that the mutants are as virulent as wild-type strains (Table  2). Presumably, other adhesins expressed by the bpaC mutants provide sufficient adherence to the murine 5-Fluoracil airway mucosa to allow colonization at wild-type levels

and for the normal course of disease to ensue. It is unlikely that the lack of phenotype we observed in vivo is due to non-expression of BpaC. Though we discovered that B. pseudomallei DD503 and B. mallei ATCC 23344 do not produce detectable amounts of BpaC under routine laboratory growth conditions, ELISA with sera from mice that survived acute aerosol infection with the agents show that animals produce Abs against the protein (Figure  4A and B). Moreover, sera from horses with experimental glanders have been shown to contain high antibody titers against BpaC [70]. These Opaganib results are particularly significant as horses are the natural host and reservoir for B. mallei and arguably the most relevant surrogate to study glanders. Together, these data demonstrate that BpaC is expressed in vivo and elicits the production of Abs during infection. The infection model we used to examine the effect of the bpaC mutation might have impacted the outcome of virulence experiments. This hypothesis is supported by the

Campos et al. study in which they show that the bpaC mutation reduces the ability of B. pseudomallei strain 340 to disseminate and/or survive in the liver [51]. DCLK1 In these experiments, BALB/c mice were infected intranasally with 500 CFU of the agent and bacterial loads in tissues were determined 48 hours post-infection. In contrast, we inoculated BALB/c mice intratracheally using a Microsprayer®, which nebulizes bacteria directly into the lungs, infected animals with doses ranging from 102 to 105 CFU, and determined bacterial burden in survivors 6–10 days post-infection (Table  2). It is also known that the choice of bacterial strains [71], inoculation route [72], and animal background [73] can significantly affect the course of disease by B. pseudomallei and B. mallei. For example, the LD50 value of the same B. pseudomallei isolate has been shown to differ by several orders of magnitude in C57BL/6 mice and BALB/c mice [74]. Therefore, a complete understanding of the role of BpaC in pathogenesis may require the use of multiple infection models.

Mathematical biosciences 2005,193(2):223–234.PubMedCrossRef 7. Poptsova MS, Gogarten JP: Using

comparative genome analysis to identify problems in annotated microbial genomes. Microbiology 2010,156(Pt 7):1909–1917.PubMedCrossRef 8. Friedberg I: Automated protein function prediction–the genomic challenge. Briefings in bioinformatics 2006,7(3):225–242.PubMedCrossRef 9. Rigden DJ: The histidine phosphatase superfamily: Structure and function. Biochem J 2008,409(2):333–348.PubMedCrossRef 10. Pilkis SJ, Lively MO, El-Maghrabi MR: Active site sequence check details of hepatic fructose-2,6-bisphosphatase. Homology in primary structure with phosphoglycerate mutase. The Journal of biological chemistry Selleckchem EPZ 6438 1987,262(26):12672–12675.PubMed 11. Fothergill LA, Harkins RN: The amino acid sequence of yeast phosphoglycerate mutase. Proc R Soc Lond B Biol Sci 1982,215(1198):19–44.PubMedCrossRef

12. Fothergill-Gilmore LA, Watson HC: The phosphoglycerate mutases. Adv Enzymol Relat Areas Mol Biol 1989, 62:227–313.PubMed 13. Fleisig H, El-Din El-Husseini A, Vincent SR: Regulation of ErbB4 phosphorylation and cleavage by a novel histidine acid phosphatase. Neuroscience 2004,127(1):91–100.PubMedCrossRef 14. Suter A, Everts V, Boyde A, Jones SJ, Lullmann-Rauch R, Hartmann D, Hayman AR, Cox TM, Evans MJ, Meister T, et al.: Overlapping functions of lysosomal acid phosphatase (LAP) and tartrate-resistant acid phosphatase (Acp5) revealed by doubly deficient mice. Development 2001,128(23):4899–4910.PubMed 15. Bazan JF, Fletterick RJ, Pilkis SJ: Evolution

of a bifunctional enzyme: 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Proc Natl Acad Sci U S A 1989,86(24):9642–9646.PubMedCentralPubMedCrossRef 16. Muller P, Sawaya MR, Pashkov I, Chan S, Nguyen C, Wu Y, Perry LJ, Eisenberg D: The 1.70 angstroms X-ray crystal structure of Mycobacterium tuberculosis phosphoglycerate mutase. Acta Crystallogr D Biol Crystallogr 2005,61(Pt 3):309–315.PubMedCrossRef 17. Mendes V, Maranha A, Alarico S, da Costa MS, Empadinhas N: Mycobacterium tuberculosis Rv2419c, the missing glucosyl-3-phosphoglycerate phosphatase for the second step in methylglucose lipopolysaccharide biosynthesis. Sci Rep 2011, Celecoxib 1:177.PubMedCentralPubMed 18. Lew JM, Kapopoulou A, Jones LM, Cole ST: TubercuList–10 years after. Tuberculosis (Edinb) 2010,91(1):1–7.CrossRef 19. Rigden DJ, Bagyan I, Lamani E, Setlow P, Jedrzejas MJ: A cofactor-dependent phosphoglycerate mutase homolog from Bacillus stearothermophilus is actually a broad specificity phosphatase. Protein Sci 2001,10(9):1835–1846.PubMedCrossRef 20. Malen H, Pathak S, Softeland T, de Souza GA, Wiker HG: Definition of novel cell envelope associated proteins in Triton X-114 extracts of Mycobacterium tuberculosis H37Rv. BMC Microbiol 2010, 10:132.PubMedCentralPubMedCrossRef 21.